Results 41 to 50 of about 5,563 (240)

Cell Therapy, Bispecific Antibodies and other Immunotherapies Against Cancer

, 2023
This Special Issue in Cancers is focused on cell therapy, bispecific antibodies, and other immunotherapies against cancer. It includes reports on cell therapies such as CAR-NK cell therapies, and bispecific antibodies against multiple myeloma and B cell ...

core   +1 more source

A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells [PDF]

, 2022
SIMPLE SUMMARY: T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive and still orphan hematologic malignancy. No effective immunotherapeutic strategies are presently available for this poor prognosis disease.
Simona Sestito, Nicoletta Polerà, Francesca Scionti, Caracciolo, Daniele, Siciliano, Maria Anna, Andrea Ballerini, Polerà, Nicoletta, Rossi, Marco, Pierfrancesco Tassone, Bonelli, Patrizia, Arbitrio, Mariamena, Tassone, Pierfrancesco, Di Martino, Maria Teresa, Patrizia Bonelli, Gentile, Massimo, Grillone, Katia, Gabriella Talarico, Loprete, Giovanni, Britti, Domenico, Riillo, Caterina, Daniele Caracciolo, Maria Anna Siciliano, Lopreiato, Mariangela, Maria Concetta Galati, Mariamena Arbitrio, Tagliaferri, Pierosandro, Marco Rossi, Ballerini, Andrea, Serena Ascrizzi, Pierosandro Tagliaferri, Galati, Maria Concetta, Pensabene, Licia, Scionti, Francesca, Maria Teresa Di Martino, Franca Maria Tuccillo, Tuccillo, Franca Maria, Sestito, Simona, Ascrizzi, Serena, Mariangela Lopreiato, Domenico Britti, Talarico, Gabriella, Katia Grillone, Riilo, Caterina, Juli, Giada, Caterina Riillo, Giada Juli, Eulalia Galea, Galea, Eulalia, Massimo Gentile, Licia Pensabene, Giovanni Loprete   +50 more
core   +1 more source

BiTEs, DARTS, BiKEs and TriKEs—Are Antibody Based Therapies Changing the Future Treatment of AML?

Life, 2021
Nearly four decades after their conceptualization, antibody-based therapies are slowly being added to the treatment landscape of acute myeloid leukemia (AML). While the antibody–drug conjugate gemtuzumab ozogamicin is the only antibody-based therapy that
Cecily Allen, Amer M. Zeidan, Jan Philipp Bewersdorf   +2 more
doaj   +1 more source

Infographic – Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas

, 2022
Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine ...
Valentina Gambardella (13027563), Enriqueta Felip (286953), Taofeek K Owonikoko (13027569), Daniel Morgensztern (10034093), Meiruo Liu (13027565), Yasutoshi Kuboki (6286328), Martin Wermke (400912), Zohra Oum’ Hamed (13027564), Figshare Future Science Group (6457551), Matus Studeny (13027566)   +9 more
core   +1 more source

Bi-, tri-, and multi-specific T-cell engager therapies in glioblastoma: a decade of preclinical innovation [PDF]

Exploration of Neuroscience
Background: Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor in adults, with a poor prognosis despite advances in treatment options. T-cell-engager therapies, which have an antibody-based structure connecting immune cells to
Adam H. Lapidus, Malaka Ameratunga
doaj   +1 more source

Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cells

Frontiers in Immunology, 2023
The activating receptor natural killer group 2, member D (NKG2D) represents an attractive target for immunotherapy as it exerts a crucial role in cancer immunosurveillance by regulating the activity of cytotoxic lymphocytes.
Sebastian Lutz, Sebastian Lutz, Katja Klausz, Anca-Maria Albici, Lea Ebinger, Lea Sellmer, Hannah Teipel, André Frenzel, Anna Langner, Dorothee Winterberg, Steffen Krohn, Michael Hust, Michael Hust, Thomas Schirrmann, Stefan Dübel, Regina Scherließ, Andreas Humpe, Martin Gramatzki, Christian Kellner, Matthias Peipp   +19 more
doaj   +1 more source

Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia [PDF]

, 2015
Targeted therapy has been the forefront of cancer treatment. Cancer immunotherapy is the most recent focus. In addition, novel immunotherapeutics targeting B cell receptor signaling (e.g., ibrutinib), T cell receptor ( e.g., CART19), and NK cells (e.g ...
Delong Liu, Jingjing Wu, Fu, Jiaping, Liu, Delong, Jiaping Fu, Wu, Jingjing, Mingzhi Zhang, Zhang, Mingzhi   +7 more
core   +1 more source

A bispecific antibody antagonizes prosurvival CD40 signaling and promotes Vγ9Vδ2 T cell-mediated antitumor responses in human B-cell malignancies

, 2021
Novel T cell-based therapies for the treatment of B-cell malignancies, such as chronic lymphocytic leukemia (CLL) and multiple myeloma (MM), are thought to have strong potential.
van de Ven, Rieneke, Kater, Arnon P., Stam, Anita G., Scheffer, George L., de Gruijl, Tanja D, de Gruijl, Tanja D., van der Vliet, Hans J, Roovers, R.C., Lameris, R., Parren, Paul W. H. I., Stam, A.G., van der Vliet, Hans J., Parren, P.W.H.I., Ven, R. van de, Scheffer, George L, Vliet, H.J. van der, Scheffer, G.L., Kater, A.P., Pals, Steven T., Weerdt, I. de, Pals, S.T., Boer, R. de, de Boer, Renate, Levin, M.D., Parren, Paul W H I, de Weerdt, Iris, Vree, Jana, Levin, Mark-David, Pals, Steven T, Stam, Anita G, Roovers, Rob C, Kater, Arnon P, Gruijl, T.D. de, Lameris, Roeland, Vree, J., Roovers, Rob C.   +35 more
core   +1 more source

Tebentafusp: a first-in-class treatment for metastatic uveal melanoma

Therapeutic Advances in Medical Oncology, 2023
Tebentafusp is a first-in-class immunotherapy agent that comprises an engineered T-cell receptor targeting a gp100 epitope presented by human leukocyte antigen-A*02:01 cells, fused to an anti-CD3 single-chain variable fragment.
Sarah Howlett, Thomas J. Carter, Heather M. Shaw, Paul D. Nathan   +3 more
doaj   +1 more source

BiTE-ing into Prostate Cancer with Bispecific T-cell Engagers

Clinical Cancer Research, 2021
Abstract Targeting prostate-specific membrane antigen (PSMA) has important therapeutic ramifications, more recently including immune oncology. Data were recently presented on the preclinical efficacy of a half-life extended bispecific T-cell engager, AMG 160, which binds PSMA and CD3 to induce T-cell–driven cytolytic activity against ...
Nikhil V. Kamat, Evan Y. Yu, John K. Lee
openaire   +3 more sources